In the related idea my price target was $1.34.
Today's high was $1.78
Check out the weekly chart:
Photo Finish.
$1.34 was 1.618 extension level from Waves 1 & 2.
Since the price-action broke $1.34 we will have an extended 3rd wave.
I expect a very strong rally tomorrow, I will update in the morning before the open to confirm.
Target is hard to predict since its impossible to know what level extending waves will terminate.
I will keep a close eye on the price-action.
Will update.
-AB
Note
As expected, a very strong rally today!Note
We got a big runway...Note
Reminder this is a WEEKLY chart...Meaning this move is far from over...
Note
Buckle up!Note
Target $2.24 (Sell Half)Trade Price: 1.049
Note
Bull FlagNote
BLRX will rally again tomorrow.Note
BLRX is about to rally again...Note
BLRX continued to consolidate today.Staying the course...
Note
Near-Term Target: $2.13Note
Primary Wave 1 CompleteNote
03:21 PM EDT, 10/22/2018 (MT Newswires) -- Oppenheimer has kept its outperform rating on BioLineRx (BLRX) with a price target of $3, betting on BL-8040's commercial opportunity as a stem cell mobilizer after top-line data from the COMBAT/KEYNOTE-202 trial of BL-8040 in combination with pembrolizumab in advanced pancreatic cancer showed modest response rate."Given the combination's favorable safety profile, BioLineRx and Merck (MRK) are testing a triplet combination including chemotherapy in an effort to increase response rate," analyst Mark Breidenbach said in a note.
"While we believe the triplet combination is worth testing, our valuation of BioLineRx still remains focused on BL-8040's commercial opportunity as a stem cell mobilizer."
Note
Breakout ImminentPublications connexes
Clause de non-responsabilité
Les informations et publications ne sont pas destinées à être, et ne constituent pas, des conseils ou recommandations financiers, d'investissement, de trading ou autres fournis ou approuvés par TradingView. Pour en savoir plus, consultez les Conditions d'utilisation.
Publications connexes
Clause de non-responsabilité
Les informations et publications ne sont pas destinées à être, et ne constituent pas, des conseils ou recommandations financiers, d'investissement, de trading ou autres fournis ou approuvés par TradingView. Pour en savoir plus, consultez les Conditions d'utilisation.
